Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study
The Oncologist · 09.03.2026 · 31 (4)
DOI: 10.1093/oncolo/oyag080 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Oncologist, online erschienen am 14.03.2026. Verfasst von Camille Guy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, CHU Lille, Service de Dermatologie, Lille, F-59000, France. Hauptthemen laut MEDLINE: Cutaneous Squamous Cell Carcinoma, Programmed Cell Death 1 Receptor, Skin Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Advanced cutaneous squamous cell carcinoma (cSCC) is associated with a poor prognosis. Although anti-Programmed cell Death protein 1 (anti-PD1) immunotherapy has improved cSCC management, its efficacy remains limited in some patients. Second-line options, including anti–epidermal growth factor receptor (anti-EGFR) antibodies and chemotherapies, exhibit transient efficacy and often good tolerability. Given the lack of successive treatment lines, new strategies are emerging, such as the combination of anti-PD1 and anti-EGFR agents. Materials and Methods We conducted a retrospective, monocentric cohort study including patients treated in our oncodermatology department between 2013 and 2024 for advanced cSCC refractory to anti-PD1 monotherapy and who received a combination of anti-PD1 and anti-EGFR as second- or third-line therapy. The aim was to assess the efficacy and safety of this combination.
Results
Fourteen patients were included, predominantly male (12/14), with a median age of 63 years. Most tumors originated from head and neck primary sites (n = 8). Eleven patients had progressed after prior exposure to both anti-PD1 therapy and cetuximab combined with chemotherapy. Thirteen patients received cetuximab (500 mg/m2) combined with pembrolizumab every 3 weeks, and 1 received cetuximab with nivolumab. The overall response rate was 38.5%, including 15.5% complete and durable response after treatment discontinuation, observed at 9 and 16 months, and 23% partial responses. Responses occurred early, with subsequent deepening observed in 2 patients. Adverse events were mainly grade 1, and only 2 cases experienced grade 3 toxicity (acneiform rash).
Conclusion
In a heavily pretreated real-life population with advanced cSCC, the anti-PD1/anti-EGFR combination showed clinical activity with acceptable safety, supporting its role as later-line strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ. Lille, CHU Lille, Service de Dermatologie, Lille, F-59000, France.
- Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.
ORCID-Profile: Laurent Mortier, Marie Boileau
Zitieren
APA
Guy, C., Hober, C., Maiezza, S., Jamme, P., Desmedt, E., Mortier, L., & Boileau, M. (2026). Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study. The Oncologist, 31(4). https://doi.org/10.1093/oncolo/oyag080
Vancouver
Guy C, Hober C, Maiezza S, Jamme P, Desmedt E, Mortier L, et al. Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study. The Oncologist. 2026;31(4). doi:10.1093/oncolo/oyag080
BibTeX
@article{Guy2026,
author = {Guy, Camille and Hober, Candice and Maiezza, Sophie and Jamme, Philipe and Desmedt, Eve and Mortier, Laurent and Boileau, Marie},
title = {Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {4},
doi = {10.1093/oncolo/oyag080}
}
EUVIMED